Overview

Bioequivalence Study of Rosuvastatin Tablet

Status:
Recruiting

Trial end date:
2022-12-15

Target enrollment:

Participant gender:

Summary

This study is designed to explore the bioequivalence of Test Product Vaptor (Rosuvastatin) 20 mg Tablet with the reference product Crestor (Rosuvastatin) 20 mg tablet under fasting conditions in healthy Pakistani male subjects.

Phase:

N/A

Details

Lead Sponsor:

University of Karachi

Collaborator:

The Searle Company Limited

Treatments:

Rosuvastatin Calcium